INTERRELATION OF THE EXPRESSION OF PROTEINS ALK, HER2 AND AMPLIFICATION OF THE GENE OF HER2 WITH THE PROLIFERATIVE ACTIVITY AND SURVIVAL IN PATIENTS WITH STAGE I-II LUNG ADENOCARCINOMA
- Authors: Panas’yan A.U.1,2, Kobyakov D.S3, Avdalyan A.M1, Ivanov A.A1, Lushnikova E.L4, Bakarev M.A4, Lazarev A.F1
-
Affiliations:
- Altai branch of the N.N. Blokhin Russian Cancer Research Center
- Altai Krai Oncology Centre
- Kogalym municipal hospital
- Institute of Molecular Pathology and Pathomorphology
- Issue: Vol 22, No 4 (2017)
- Pages: 209-213
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40388
- DOI: https://doi.org/10.18821/1028-9984-2017-22-4-209-213
- ID: 40388
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Artak U. Panas’yan
Altai branch of the N.N. Blokhin Russian Cancer Research Center; Altai Krai Oncology Centre
Email: urartu26@yandex.ru
MD, Researcher of the Department for the Development of Modern Methods of Treatment in Thoracic Oncology of the Altai Branch of the N.N. Blokhin Russian Cancer Research Center; Barnaul, 656049, Russian Federation Barnaul, 656049, Russian Federation; Barnaul, 656043, Russian Federation
D. S Kobyakov
Kogalym municipal hospitalKogalym, 628481, Russian Federation
A. M Avdalyan
Altai branch of the N.N. Blokhin Russian Cancer Research CenterBarnaul, 656049, Russian Federation
A. A Ivanov
Altai branch of the N.N. Blokhin Russian Cancer Research CenterBarnaul, 656049, Russian Federation
E. L Lushnikova
Institute of Molecular Pathology and PathomorphologyNovosibirsk, 630117, Russian Federation
M. A Bakarev
Institute of Molecular Pathology and PathomorphologyNovosibirsk, 630117, Russian Federation
A. F Lazarev
Altai branch of the N.N. Blokhin Russian Cancer Research CenterBarnaul, 656049, Russian Federation
References
- Warth A., Penzel R., Lindenmaier H., Brandt R., Stenzinger A., Herpel E. et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur. Respir. J. 2014; 43: 872-3.
- Zhao F., Xu M., Lei H., Zhou Z., Wang L., Li P. et al. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusiongene: a meta-analysis. PLoS One. 2015; 10(2): e0117333.
- Nakamura H., Saji H., Ogata A., Hosaka M., Hagiwara M., Kawasaki N. et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int. J. Cancer. 2003; 103: 61-6.
- Al-Saad S., Al-Shibli K., Donnem T., Andersen S., Bremnes R.M., Busund L.T. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. J. Thorac. Oncol. 2010; 5: 1536-43.
- Beresford M.J., Wilson G.D., Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006; 8: 216.
- Jakobsen J.N., Sorensen J.B. Clinical impact of Ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013; 79: 1-7.
- Del Gobbo A., Pellegrinelli A., Gaudioso G., Castellani M., Zito Marino F., Franco R. et al. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology. 2016; 68: 746-51.
- Pelosi G., Del Curto B., Dell’Orto P., Pasini F., Veronesi G., Spaggiari L. et al. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int. J. Cancer. 2005; 113: 101-8.
- Tan D., Deeb G., Wang J., Slocum H.K., Winston J., Wiseman S. et al. HER-2/neu protein expression and gene alteration in stage I-IIIA nonsmall-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol. 2003; 12: 201-11.
- Yang P., Kulig K., Boland J.M., Erickson-Johnson M.R., Oliveira A.M., Wampfler J. et al. Worse disease-free survival in never-smokers with ALK lung adenocarcinoma. J. Thorac. Oncol. 2012; 7: 90-7.
- Lee J.K., Park H.S., Kim D.W., Kulig K., Kim T.M., Lee S.H. et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer. 2012; 118: 3579-86.
- Wu S.G., Kuo Y.W., Chang Y.L., Shih J.Y., Chen Y.H., Tsai M.F. et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J. Thorac. Oncol. 2012; 7: 98-104.
- Sobin L., Gospodarowicz M., Wittekind C. (Eds.). TNM Classification of Malignant Tumours. 7th Ed. Oxford: Wiley-Blackwell; 2009: 138-46.
- Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y. et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011; 6: 244-85.
- Hofmann M., Stoss O., Shi D., Bьttner R., van de Vijver M., Kim W. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52: 797-805.
- Wang S., Hossein Saboorian M., Frenkel E.P., Haley B.B., Siddiqui M.T., Gokaslan S. et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod. Pathol. 2002; 15: 137-45.
- Siraj A.K., Beg S., Jehan Z., Prabhakaran S., Ahmed M., Hussain A.R. et al. ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res. 2015; 17: 127.
- Shokouh T.Z., Ezatollah A., Barand P. Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: retrospective-observational analytical study. Medicine (Baltimore). 2015; 94: e1359.
- Nogi H., Uchida K., Kamio M., Kato K., Toriumi Y., Akiba T. et al. Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIб. Mol. Clin. Oncol. 2016; 4: 383-9.
- Payandeh M., Shahriari-Ahmadi A., Sadeghi M., Sadeghi E. Correlations between HER2 expression and other prognostic factors in breast cancer: Inverse relations with the Ki-67 index and P53 status. Asian. Pac. J. Cancer Prev. 2016; 17: 1015-8.